Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, McLean CA, Villemagne VL, Parker MW, Barnham KJ, Miles LA.

Acta Neuropathol. 2014;127(6):803-10. doi: 10.1007/s00401-014-1290-2. Epub 2014 May 7.

PMID:
24803227
2.

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

Bouter Y, Lopez Noguerola JS, Tucholla P, Crespi GA, Parker MW, Wiltfang J, Miles LA, Bayer TA.

Acta Neuropathol. 2015 Nov;130(5):713-29.

PMID:
26467270
3.

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

Panza F, Solfrizzi V, Imbimbo BP, Logroscino G.

Expert Opin Biol Ther. 2014 Oct;14(10):1465-76. doi: 10.1517/14712598.2014.935332. Epub 2014 Jun 30. Review.

PMID:
24981190
4.

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Review.

PMID:
22339463
5.

Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies.

Zhao J, Nussinov R, Ma B.

J Biol Chem. 2017 Nov 3;292(44):18325-18343. doi: 10.1074/jbc.M117.801514. Epub 2017 Sep 18.

PMID:
28924036
6.

Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.

Fuller JP, Stavenhagen JB, Christensen S, Kartberg F, Glennie MJ, Teeling JL.

Acta Neuropathol. 2015 Nov;130(5):699-711. doi: 10.1007/s00401-015-1484-2. Epub 2015 Oct 3.

7.

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.

Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A.

Expert Opin Biol Ther. 2011 Jun;11(6):679-86. doi: 10.1517/14712598.2011.579099. Epub 2011 Apr 19.

PMID:
21501112
8.

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.

Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G.

Expert Rev Clin Immunol. 2014 Mar;10(3):405-19. doi: 10.1586/1744666X.2014.883921. Epub 2014 Feb 4. Review.

PMID:
24490853
9.

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.

Crespi GA, Hermans SJ, Parker MW, Miles LA.

Sci Rep. 2015 Apr 16;5:9649. doi: 10.1038/srep09649.

10.

Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.

Ribeiro CA, Oliveira SM, Guido LF, Magalhães A, Valencia G, Arsequell G, Saraiva MJ, Cardoso I.

J Alzheimers Dis. 2014;39(2):357-70. doi: 10.3233/JAD-131355.

PMID:
24169237
11.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V.

Immunotherapy. 2010 Nov;2(6):767-82. doi: 10.2217/imt.10.80. Review.

PMID:
21091109
12.

Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

Panza F, Logroscino G, Imbimbo BP, Solfrizzi V.

Curr Opin Psychiatry. 2014 Mar;27(2):128-37. doi: 10.1097/YCO.0000000000000041. Review.

PMID:
24445401
13.

Identification of N-terminally truncated pyroglutamate amyloid-β in cholesterol-enriched diet-fed rabbit and AD brain.

Perez-Garmendia R, Hernandez-Zimbron LF, Morales MA, Luna-Muñoz J, Mena R, Nava-Catorce M, Acero G, Vasilevko V, Viramontes-Pintos A, Cribbs DH, Gevorkian G.

J Alzheimers Dis. 2014;39(2):441-55. doi: 10.3233/JAD-130590.

PMID:
24240639
14.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

15.

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.

Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F.

Expert Rev Clin Immunol. 2012 Feb;8(2):135-49. doi: 10.1586/eci.11.93. Review.

PMID:
22288451
16.

Solanezumab for Alzheimer's disease.

Samadi H, Sultzer D.

Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi: 10.1517/14712598.2011.578573. Epub 2011 Apr 20. Review.

PMID:
21504387
17.

Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.

Panza F, Solfrizzi V, Imbimbo BP, Giannini M, Santamato A, Seripa D, Logroscino G.

Expert Rev Neurother. 2014 Sep;14(9):973-86. doi: 10.1586/14737175.2014.945522. Epub 2014 Aug 1. Review.

PMID:
25081412
18.

Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.

Wu G, Miller RA, Connolly B, Marcus J, Renger J, Savage MJ.

Neurodegener Dis. 2014;14(2):53-66. doi: 10.1159/000353634. Epub 2013 Oct 23.

PMID:
24158021
19.

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG.

J Alzheimers Dis. 2011;24(2):315-25. doi: 10.3233/JAD-2011-101809.

20.

Amyloid beta peptide immunotherapy in Alzheimer disease.

Delrieu J, Ousset PJ, Voisin T, Vellas B.

Rev Neurol (Paris). 2014 Dec;170(12):739-48. doi: 10.1016/j.neurol.2014.10.003. Epub 2014 Nov 6. Review.

PMID:
25459121

Supplemental Content

Support Center